The field of managed care has evolved greatly over the last 20 years, and The American Journal of Managed Care has kept those in the industry up to date with changes, said Risa Lavizzo-Mourey, MD, MBA, president and CEO of the Robert Wood Johnson Foundation.
president and CEO of the Robert Wood Johnson Foundation, said when congratulating the journal on its anniversary.
Read Dr Lavizzo-Mourey's special guest commentary or visit our 20th anniversary page for more special content.
The field of managed care has evolved greatly over the last 20 years, and during that time The American Journal of Managed Care has evolved as well and kept those in the industry up to date with changes, Risa Lavizzo-Mourey, MD, MBA,
Transcript (slightly modified for readability):
I understand that The American Journal of Managed Care is about to celebrate its 20th anniversary, so I want to be among the first to wish you "happy birthday" and congratulate you on being the kind of publication that continued to evolve as the field evolved. Managed care is a very complex area, and as we have seen over the last 20 years, it has changed tremendously. So congratulations to you for helping all of us in the field stay with it.
Managed care is continuing to evolve and I think what we really need is for it to continue to take into account the triple aim—that is high-quality healthcare, high-quality population health, and lower healthcare costs. If managed care can move from not only addressing the individual needs of patients or populations of patients to the needs of the entire population I think we'll truly have a delivery mechanism that matches what we need as a country.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More